# US 7,612,046 B2 · Method for treating kidney disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,612,046 B2
- Document ID: US7612046B2
- Status: Granted
- Kind: B2
- Application number: 10/182,680
- Filed: 2001-01-31
- Published: 2003-07-03
- Granted: 2009-11-03
- Earliest claimed: 2000-01-31
- Inventors: Uwe Waldemar Rothenpieler; Michael Carl Elmar Imgrund
- Web page: https://patentgrep.com/patent/US7612046B2

## CPC

- A61K 38/1709: {from mammals}
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a cellular therapy of renal failure, i.e. preventing, delaying, and treating acute/chronic renal failure via the use of an effective dose of a substance capable of inducing and/or enhancing Pax2 expression in a mammal for the preparation of a pharmaceutical composition for treating, preventing or delaying a renal dysfunction/failure in a mammal. Additionally, the present invention provides for a method for converting mesenchymal tissue into an epithelial tissue comprising the administration of an effective amount of a substance capable of inducing and/or enhancing Pax2 expression in mesenchymal tissue and for a method for the regeneration of renal stem cells comprising the administration of an effective amount of a substance capable of inducing and/or enhancing Pax2 expression.

## Claims

### Claim 1

A method for regenerating tubular epithelium in a mammal patient affected by acute tubular necrosis comprising administering directly to the kidney of said mammal patient a therapeutically effective amount of a composition comprising a vector comprising a nucleic acid molecule encoding Pax2a or Pax2b protein, wherein said nucleic acid molecule is operatively linked to an expression control sequence.

### Claim 2 (depends on 1)

The method of claim 1, wherein said vector is an expression vector, a gene targeting vector or a gene transfer vector.

### Claim 3 (depends on 1)

The method of claim 1, wherein said composition is administered by injection and said therapeutically effective amount is in the range of 1 μg to 5 g.

### Claim 4 (depends on 1)

The method of claim 1, wherein said composition causes an increase in Pax2a or Pax2b expression in the cells of the proximal tubuli in the kidney of the patient.

### Claim 5 (depends on 1)

The method of claim 1, wherein said patient is a human.

### Claim 6

A method for generating epithelial cysts from mesenchymal cells in vitro comprising transforming said cells with a vector comprising a nucleic acid molecule encoding Pax2a or Pax2b protein, wherein said nucleic acid molecule is operatively linked to an expression control sequence.

### Claim 7 (depends on 6)

The method of claim 6, wherein said mesenchymal cells are isolated from a mammal.

### Claim 8 (depends on 6)

The method of claim 6, wherein said mesenchymal cells are isolated from a human.